Onesource Specialty Pharma Intrinsic Value
Onesource Specialty Pharma (ONESOURCE) median intrinsic value is ₹665.34 from 7 valuation models (range ₹464–₹3863), vs current price ₹1545.10 — -56.9% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit ONESOURCE stock live price.
ONESOURCE Valuation Methods Summary — DCF, Graham Number & P/E
Onesource Specialty Pharma intrinsic value across 7 models vs current price ₹1545.10 — upside/downside and value range per method. Browse ONESOURCE cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹463.53 | ₹370.82 - ₹556.24 | -70.0% | EPS: ₹3.68, Sector P/E: 22x |
| Book Value Method | asset | ₹3862.75 | ₹3476.47 - ₹4249.03 | +150.0% | Book Value/Share: ₹5346.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2756.36 | ₹2480.72 - ₹3032.00 | +78.4% | Revenue/Share: ₹1378.18, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3090.20 | ₹2781.18 - ₹3399.22 | +100.0% | EBITDA: ₹440.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹463.53 | ₹417.18 - ₹509.88 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹463.53 | ₹417.18 - ₹509.88 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹665.34 | ₹598.81 - ₹731.87 | -56.9% | EPS: ₹3.68, BVPS: ₹5346.36 |
ONESOURCE Intrinsic Value vs Market Price — All Valuation Models
Onesource Specialty Pharma fair value range ₹464–₹3863 vs current market price ₹1545.10 across 7 valuation models. Compare with Onesource Specialty Pharma value estimation to assess whether the stock is under or overvalued.
ONESOURCE Intrinsic Value Analysis — Undervalued or Overvalued?
Onesource Specialty Pharma median intrinsic value ₹665.34, current price ₹1545.10 — Trading Above Calculated Value by 56.9%, margin of safety -100.0%.
What is the intrinsic value of ONESOURCE?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Onesource Specialty Pharma (ONESOURCE) is ₹665.34 (median value). With the current market price of ₹1545.10, this represents a -56.9% variance from our estimated fair value.
The valuation range spans from ₹463.53 to ₹3862.75, indicating ₹463.53 - ₹3862.75.
Is ONESOURCE undervalued or overvalued?
Based on our multi-method analysis, Onesource Specialty Pharma (ONESOURCE) appears to be trading above calculated value by approximately 56.9%.
ONESOURCE Financial Health — Key Ratios vs Industry Benchmarks
Onesource Specialty Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.95 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 0.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 28.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.20x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ONESOURCE Cash Flow Quality — Operating & Free Cash Flow
Onesource Specialty Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-68 Cr | ₹-169 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-107 Cr | ₹-107 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-163 Cr | ₹-197 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-416 Cr | ₹-762 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-118 Cr | ₹-222 Cr | Negative Cash Flow | 3/10 |